Aurobindo to purchase Lannett Co.

EAST WINDSOR, N.J. — Aurobindo Pharma USA (Aurobindo) has proposed the acquisition of Lannett Co. (Lannett). The company says it anticipates closing the acquisition towards the middle of calendar 2026, subject to regulatory approval.

"Over the coming months, we will be providing additional updates on this exciting acquisition and how we expect it to enable us to better serve you, our valued customer," said Paul McMahon, president, APUSA Oral Solids Division at Aurobindo. "In the meantime, until the transaction closes, it will be business as usual in every respect with both Aurobindo and Lannett continuing to operate as separate entities. Please continue to work with your respective points of contact at Aurobindo and Lannett for any of your normal day-to-day business needs regarding the respective product portfolios, operational and transactional matters, etc," he added.